Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis.
作者信息
Andonopoulos A P, Meimaris N, Daoussis D, Bounas A, Giannopoulos G
机构信息
Department of Medicine, Division of Rheumatology, University of Patras School of Medicine, Patras, Greece.
出版信息
Ann Rheum Dis. 2003 Nov;62(11):1116. doi: 10.1136/ard.62.11.1116.
Abstract
摘要
相似文献
1
Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis.
Ann Rheum Dis. 2003 Nov;62(11):1116. doi: 10.1136/ard.62.11.1116.
2
Infliximab as monotherapy in giant cell arteritis.
Clin Rheumatol. 2006 Feb;25(1):109-10. doi: 10.1007/s10067-005-1115-8. Epub 2005 May 18.
3
Infliximab efficiency and failure.
Ann Rheum Dis. 2004 Jun;63(6):751-2; author reply 752.
4
Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs.
Rheumatology (Oxford). 2002 Mar;41(3):347-9. doi: 10.1093/rheumatology/41.3.347.
5
Treatment of longstanding active giant cell arteritis with infliximab: report of four cases.
Arthritis Rheum. 2001 Dec;44(12):2933-5. doi: 10.1002/1529-0131(200112)44:12<2933::aid-art482>3.0.co;2-y.
6
Summaries for patients. Adding infliximab to the treatment regimen for giant cell arteritis.
Ann Intern Med. 2007 May 1;146(9):I12. doi: 10.7326/0003-4819-146-9-200705010-00001.
7
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.
Ann Intern Med. 2007 May 1;146(9):621-30. doi: 10.7326/0003-4819-146-9-200705010-00004.
8
[Infliximab is ineffective against giant cell arteritis and polymyalgia rheumatica].
Z Rheumatol. 2007 Oct;66(6):536-7. doi: 10.1007/s00393-007-0210-4.
9
Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward?
Ann Intern Med. 2007 May 1;146(9):674-6. doi: 10.7326/0003-4819-146-9-200705010-00011.
10
Tumor necrosis factor blocking agents in polymyalgia rheumatica and giant cell arteritis.
Ann Intern Med. 2008 Jan 15;148(2):167-8; author reply 168. doi: 10.7326/0003-4819-148-2-200801150-00018.
引用本文的文献
1
Unmet Needs in the Pathogenesis and Treatment of Vasculitides.
Clin Rev Allergy Immunol. 2018 Apr;54(2):244-260. doi: 10.1007/s12016-017-8643-2.
2
The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
PLoS One. 2014 Dec 17;9(12):e115026. doi: 10.1371/journal.pone.0115026. eCollection 2014.
3
Biologic agents in systemic vasculitis.
Int J Clin Rheumtol. 2011;6(4):453-462. doi: 10.2217/IJR.11.29.
4
New indications for biological therapies.
Intern Emerg Med. 2011 Oct;6 Suppl 1:1-9. doi: 10.1007/s11739-011-0667-7.
5
Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.
Drugs Aging. 2011 Aug 1;28(8):651-66. doi: 10.2165/11592500-000000000-00000.
6
Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial.
Arthritis Res Ther. 2010;12(5):R176. doi: 10.1186/ar3140. Epub 2010 Sep 20.
7
Advances in the use of biologic agents for the treatment of systemic vasculitis.
Curr Opin Rheumatol. 2009 Jan;21(1):3-9. doi: 10.1097/BOR.0b013e32831d28b3.
8
Neuro-ophthalmic complications in giant cell arteritis.
Curr Allergy Asthma Rep. 2008 Jul;8(4):323-30. doi: 10.1007/s11882-008-0052-4.
9
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430.
10
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii2-15. doi: 10.1136/ard.2006.061937.
Zotero 插件